Phase Ib Study of Alternating Neoadjuvant Gemcitabine-Nab-Paclitaxel and Nanoliposomal Irinotecan (Nal-IRI) With 5-Fluorouracil and Folinic Acid (Leucovorin) Regimens in Resectable and Borderline Resectable Pancreatic Cancer
Summary
The purpose of this phase Ib trial is to evaluate the safety, tolerability and feasibility of alternative neoadjuvant gemcitabine-nab-paclitaxel and nal-IRI with 5-Fluorouracil (5FU) and folinic acid (Leucovorin) regimens in patients with localized cancer.
General Information
NCT#: NCT03703063
Study ID: CRP17118
Trial Phase: Phase I
Trial Sponsor: Benaroya Research Institute
Therapies Used in This Trial: Nab-paclitaxel, Fluorouracil, Gemcitabine, Leucovorin, irinotecan liposome injection